|
|
Article: HIV Study Adding African Site For Targeted Genetics' Product.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Washington Editor
HIV researchers are enlisting a gene therapy product in an expanding study that's under way in southern Africa.
The newest portion of the trial is a collaborative effort between the Zambia Emory HIV Research Project, the International AIDS Vaccine Initiative (IAVI) and Targeted Genetics Corp. to test the safety and immunogenicity of a preventive HIV vaccine, tgAAC09. The product is Targeted Genetics' and based on HIV subtype C, the subtype of the virus most prevalent in southern Africa.
It employs a recombinant adeno-associated viral (AAV) vector to deliver select HIV genes. The naturally occurring virus is seen as ...